Cyclosporine protects the heart during aortic valve surgery

Anesthesiology

Volumn 121, Issue 2, 2014, Pages 232-238

  Chiari, Pascal ^a,d   Angoulvant, Denis ^e   Mewton, Nathan ^a,b,d   Desebbe, Olivier ^a   Obadia, Jean François ^c,d   Robin, Jacques ^c   Farhat, Fadi ^c   Jegaden, Olivier ^c,d   Bastien, Olivier ^a   Lehot, Jean Jacques ^a   Ovize, Michel ^a,b,d  

^a Department of Anesthesiology and Critical Care ^*  (France)

^b Department of Clinical Pharmacology   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; TROPONIN I;

ABSENCE OF SIDE EFFECTS; ADULT; AORTA CLAMPING; AORTA VALVE; AORTA VALVE SURGERY; ARTICLE; CARDIAC PATIENT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HEART VALVE SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SINGLE BLIND PROCEDURE; SURGICAL PATIENT; TREATMENT OUTCOME;

AGED; ANESTHESIA; AORTIC VALVE; CYCLOSPORINE; ECHOCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HEART DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SAMPLE SIZE; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TROPONIN I;

EID: 84904868198     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000331     Document Type: Article

References (22)

1. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L: Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15:816-22; discussion 822-3
2. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio- Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation 2007; 116:2634-53
3. Croal BL, Hillis GS, Gibson PH, Fazal MT, El-Shafei H, Gibson G, Jeffrey RR, Buchan KG, West D, Cuthbertson BH: Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation 2006; 114:1468-75
4. Fellahi JL, Hanouz JL, Le Manach Y, Gué X, Monier E, Guillou L, Riou B: Simultaneous measurement of cardiac troponin I, B-type natriuretic peptide, and C-reactive protein for the prediction of long-term cardiac outcome after cardiac surgery. Anesthesiology 2009; 111:250-7
5. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007; 357:1121-35
6. Javadov S, Karmazyn M: Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 2007; 20:1-22
7. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M: Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359:473-81
8. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC: Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 2005; 102:102-9
9. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63
10. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285:H579-88
11. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H: Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960; 70:68-78
12. Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R, Perrelli MG, Mancardi D, Pagliaro P: Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 2009; 104:390-402
13. Rodríguez-Sinovas A, Cabestrero A, García del Blanco B, Inserte J, García A, García-Dorado D: Intracoronary acid infusion as an alternative to ischemic postconditioning in pigs. Basic Res Cardiol 2009; 104:761-71
14. Manintveld OC, Te Lintel Hekkert M, van den Bos EJ, Suurenbroek GM, Dekkers DH, Verdouw PD, Lamers JM, Duncker DJ: Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 2007; 292:H1551-60
15. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R; Working Group of Cellular Biology of Heart of European Society of Cardiology: Postconditioning and protection from reperfusion injury: Where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87:406-23
16. Joiner ML, Koval OM, Li J, He BJ, Allamargot C, Gao Z, Luczak ED, Hall DD, Fink BD, Chen B, Yang J, Moore SA, Scholz TD, Strack S, Mohler PJ, Sivitz WI, Song LS, Anderson ME: CaMKII determines mitochondrial stress responses in heart. Nature 2012; 491:269-73
17. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M: Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005; 38:367-74
18. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, LHuillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M: Postconditioning the human heart. Circulation 2005; 112:2143-8
19. Mewton N, Thibault H, Roubille F, Lairez O, Rioufol G, Sportouch C, Sanchez I, Bergerot C, Cung TT, Finet G, Angoulvant D, Revel D, Bonnefoy-Cudraz E, Elbaz M, Piot C, Sahraoui I, Croisille P, Ovize M: Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol 2013; 108:383
20. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, André-Fouët X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M: Long-term benefit of postconditioning. Circulation 2008; 117:1037-44
21. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I, Cung TT, Sportouch C, Angoulvant D, Finet G, André-Fouët X, Derumeaux G, Piot C, Vernhet H, Revel D, Ovize M: Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010; 55:1200-5
22. Li J, Iorga A, Sharma S, Youn JY, Partow-Navid R, Umar S, Cai H, Rahman S, Eghbali M: Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology 2012; 117:836-46